CAT-2003 + statin

CAT-2003 + statin is a **combination therapy** of CAT-2003, a novel conjugate of eicosapentaenoic acid (EPA) and niacin, with a statin (typically atorvastatin). CAT-2003 is designed to be hydrolyzed intracellularly, releasing EPA and niacin; it inhibits the maturation of sterol regulatory element-binding protein (SREBP)-1 and SREBP-2 and downregulates SREBP target genes like HMGCR and PCSK9[1][7]. Statins inhibit HMG-CoA reductase, directly reducing cholesterol synthesis. Combined, CAT-2003 and statins lower LDL cholesterol and triglycerides more than either alone, demonstrating additive and possibly synergistic effects in preclinical and early clinical trials[1][2][5][6][7]. CAT-2003 also reduces hepatic inflammation and steatosis, and the combination is investigated primarily for severe hypertriglyceridemia and hypercholesterolemia, including in statin-treated patients[2][3][5][7].

Other names

CAT-2003 plus statinCAT2003 plus statinCAT 2003 plus statinCAT-2003 in combination with statinCAT2003 in combination with statinCAT 2003 in combination with statin